What are inhaled corticosteroids, really?
Inhaled corticosteroids — ICS for short — are the daily inhaler you take when nothing is wrong, precisely so that nothing goes wrong. That sentence sounds like a riddle, and it is the single most misunderstood thing about the whole class. People expect a medicine to do something they can feel. This one earns its keep on the boring days.
Here is the split that matters. There are two completely different kinds of asthma inhaler, and mixing them up is the most common and most dangerous mistake a patient can make. A reliever (a short-acting bronchodilator, like the classic blue albuterol/salbutamol puffer) pries open airways that are already clamping down — fast, dramatic, over in minutes. A controller does the opposite job on the opposite timeline: it keeps the airway lining calm week after week so the clamping-down happens far less often. Inhaled corticosteroids are the controller. They are not bronchodilators. They open nothing in a hurry. If you are gasping, an ICS is not the puffer you reach for.
The household names all belong to the same family: budesonide (Pulmicort), fluticasone (Flovent, Flixotide), beclomethasone (QVAR), ciclesonide (Alvesco) and mometasone (Asmanex). One quick label warning — budesonide also shows up as Rhinocort, which is a nasal spray for hay fever, not a lung inhaler. Same molecule, different address in the body.
The word "corticosteroid" makes people flinch, and understandably — steroids have a heavy reputation, which we cover in our companion piece on systemic corticosteroids. But the whole point of an inhaled steroid is that it is not systemic. And that difference is not marketing. It is chemistry, and it is the reason this class exists.
How they work — the simple version
Think of asthma not as a plumbing problem but as a skin problem that happens to be inside your chest. The airways of someone with asthma are chronically irritated and swollen, twitchy, quick to overreact to cold air, exercise, pollen or a passing cold. That underlying inflammation is the real disease. The wheeze is just the moment it boils over.
Down at the cellular level, an inhaled steroid works the same way its oral cousins do — we walk through that machinery in detail in the systemic corticosteroids article, so here is the short version. The molecule slips into airway cells, finds a docking protein called the glucocorticoid receptor, and rides it into the nucleus. There it quietly rewrites the cell's to-do list, shutting down the master switches (with names like NF-κB) that order up the inflammatory alarm signals. The specific alarms it silences — cytokines such as IL-4, IL-5 and IL-13 — are the ones that summon eosinophils, swell the airway lining and flood it with mucus. Turn those signals down and the wall thins out, the eosinophils drain away, and the airway stops being a hair-trigger. Rhen and Cidlowski mapped this anti-inflammatory mechanism in a much-cited review (New England Journal of Medicine, 2005).
Now the part everyone gets wrong: this takes time. An ICS is not a switch, it is a slow simmer-down. Think of it like watering a brown lawn. You will not see green tomorrow, or the day after. But keep watering, and in a couple of weeks the whole yard has quietly recovered — and if you stop, it browns out again just as slowly. The full anti-inflammatory benefit builds over days to weeks. If you judge an ICS after two days, you will conclude it does nothing, and you will be wrong in the most expensive possible way.
Then there is the elegant engineering that separates the inhaled steroids from the oral ones. When you puff, most of the drug lands where you want it — the airway lining — but a chunk inevitably gets swallowed. The molecules are designed so that swallowed fraction is a dead end. Fluticasone, for example, is shredded by the liver on its first pass through, so almost none of it reaches the rest of your body. Ciclesonide goes further and arrives as an inactive prodrug that only enzymes in the lung switch on, then the body rapidly deactivates it once it drifts elsewhere. The net effect is that at doses producing the same airway benefit, whole-body steroid exposure runs a tiny fraction of what an oral prednisolone tablet delivers (Lipworth, Archives of Internal Medicine, 1999). This is the entire reason ICS can be taken every day for years while oral steroids cannot.
What else they do to your body, beyond calming your airways
No drug delivers only the effect you paid for, and ICS are honest about their bill — it is just a much smaller bill than the oral version. The side effects sort neatly into two piles: the local ones, which are common and annoying but harmless, and the systemic ones, which are rare at sensible doses but real at high ones.
The local pile — the throat, not the lungs. The two most common complaints have nothing to do with the airways at all. They come from the drug that missed the lungs and settled in the mouth and throat. One is oral thrush (candidiasis): white patches on the tongue or throat, sometimes soreness when you swallow — a fungus taking advantage of the local steroid dampening the mouth's defenses. The other is a hoarse, gravelly voice (dysphonia), from steroid settling on the vocal cords. Two habits can reduce these risks: rinse your mouth and spit after every dose, and use a spacer with a metered-dose inhaler so less drug fogs the back of your throat. GINA builds this rinse-and-spacer advice straight into its guidance.
The systemic pile — small at low doses, real at high ones. Because a little steroid does escape into the bloodstream, high doses taken over long stretches can do faint versions of what oral steroids do. The body can dial down its own cortisol production (HPA-axis suppression), bone density can drift lower, and — the one that worries parents most — children on higher long-term doses can grow a little more slowly. That last effect is genuine and dose-related; most children largely catch up, though not always completely (Lipworth, Archives of Internal Medicine, 1999). At the very high, long-term end, ICS carry a small added risk of cataracts and raised eye pressure (glaucoma). The theme is consistent: every systemic effect of oral steroids has a pale, shrunken echo in the inhaled world. The dose is the dial that turns those echoes up or down, which is why doctors always chase the lowest dose that keeps the disease quiet.
The COPD exception — pneumonia. There is one systemic effect that is not just a faded copy: in people with COPD (not asthma), inhaled steroids modestly raise the risk of pneumonia. This showed up repeatedly in the trials, the mechanism is still debated, and it appears to be a genuine class effect in this population (Suissa et al., Thorax, 2013). It does not make ICS wrong for COPD — it makes them a choice you weigh rather than a default, which is exactly how the COPD guidelines treat them.
Put the two piles together and you get the honest headline: for most adults at standard controller doses, the systemic effects are clinically small, and the trade — a calm airway in exchange for a rinse-and-spit habit — is one of the better deals in medicine.
What people usually take with them, and why
An inhaled steroid rarely travels alone once asthma moves past the mild end. Its most common companion is a LABA — a long-acting beta-2 agonist, the slow-burn cousin of the fast reliever. The LABA keeps the airways gently propped open all day; the ICS keeps the inflammation from building in the first place. They tackle different halves of the same problem, which is why they are so often packed into a single inhaler: fluticasone/salmeterol (Advair, Seretide), budesonide/formoterol (Symbicort), fluticasone furoate/vilanterol (Breo, Relvar). One inhaler instead of two is not just convenience — it is adherence, and adherence is where asthma control is usually won or lost. GINA positions ICS-LABA as a preferred controller step for adults who need more than an inhaled steroid alone.
There is also a genuinely clever wrinkle that GINA now endorses, and it hinges on one specific LABA. Formoterol, unlike the others, acts fast enough to double as a reliever. That makes budesonide/formoterol a single inhaler you can use both as your daily controller and as your rescue puff when symptoms flare — the approach called SMART or MART (maintenance and reliever therapy). The beauty of it is that every time you reach for relief, you also deliver a dose of anti-inflammatory, so the sicker you feel, the more controller you automatically take. The foundational trial for this idea followed budesonide/formoterol used exactly this way and found it cut severe flares (O'Byrne et al., American Journal of Respiratory and Critical Care Medicine, 2005). GINA now lists ICS-formoterol as a preferred track across several treatment steps.
COPD is a different country. Here ICS are the exception, not the rule. GOLD recommends an ICS-containing regimen mainly for the subset of COPD patients who keep having exacerbations and who have higher blood eosinophil counts — a biological signal that steroid-responsive inflammation is in play. For those with severe disease and stubborn flares, the combination climbs to triple therapy: ICS plus a LABA plus a LAMA (a long-acting muscarinic antagonist), all in one device. But a person with stable COPD and no eosinophil signal often does better without an inhaled steroid — remember the pneumonia risk — which is why GOLD treats the ICS decision in COPD as a deliberate, evidence-weighed call rather than an automatic add-on.
Oral steroids alongside an inhaler. Short courses are used for some severe exacerbations. Long-term oral steroids are generally avoided because of their adverse effects, but may still be a last-resort specialist option in selected severe asthma cases. Do not stop an existing oral-steroid regimen yourself.
Red flags — when to call a doctor
An inhaled steroid is a background medicine, but a few signals mean the background needs attention now — and one or two mean an emergency room.
- You are reaching for your reliever more than a couple of times a week (pre-exercise puffs aside). This is the single most important warning sign in all of asthma care: frequent rescue use means the disease is not controlled, and per GINA it is a prompt to revisit the controller plan — not to simply buy more reliever.
- An attack that does not ease within about 15–20 minutes of using your reliever, or that keeps coming back. That is an emergency. Seek urgent care.
- White patches in the mouth or throat, or pain on swallowing. Likely oral thrush from the ICS — treatable, but it needs a look, and it is a nudge to tighten your rinse-and-spacer technique.
- A hoarse voice that does not clear up once you have fixed the rinsing and spacer habit. Persistent dysphonia deserves a clinical check rather than a shrug.
- A child on an inhaled steroid whose growth curve has flattened. Not a reason to stop the medicine on your own, but a real reason to sit down with the paediatrician and reassess the dose.
- On a high-dose ICS and feeling wrung-out, dizzy, nauseated — especially while ill. In rare cases this can signal that the body's own cortisol production has been suppressed and cannot rise to meet the stress of illness. Do not tough it out; call.
What people get wrong
"It's not working — I've taken it for two days and I feel the same." Of course you do. An ICS is not a painkiller and not a reliever; it prevents inflammation over weeks, not hours. Judging it after two days is like weighing yourself two days into a diet and concluding food doesn't matter. Give it the weeks it needs.
"I feel fine now, so I can stop." This is the one that lands people in the hospital. Asthma is not cured when you feel well — the airway inflammation is simply quiet, and it comes right back when the medicine stops. Controllers work like blood-pressure pills: you take them on the good days because they are what makes the days good. Stopping because you feel fine is stopping the very thing responsible for feeling fine.
"If I have no symptoms, there's nothing to treat." Same trap, worth stating twice. Airway inflammation smoulders on even during symptom-free stretches. That calm period is not proof the disease is gone; it is exactly the window in which the ICS is quietly preventing the next flare.
"Inhaled steroids are the same as steroid tablets." They share pharmacology, but delivery to the airways usually limits whole-body exposure at usual doses. There is no single valid multiplier comparing every inhaler with oral prednisolone: molecule, dose, device and other medicines all matter. Systemic effects remain possible.
"They're as harmless as vitamins, then." Also no — the other overcorrection. At high doses, over years, the systemic effects are real, especially in children. "Much safer than oral steroids" is true; "risk-free" is not. That is precisely why the goal is always the lowest dose that keeps the airways calm.
"They are addictive because symptoms return after stopping." They do not usually cause craving or addiction. Symptoms often return because the asthma is no longer controlled. Prolonged high-dose treatment can also suppress the adrenal glands, so treatment changes should be planned with the clinician.
"All inhalers are basically the same, so technique doesn't matter." It matters enormously. A metered-dose inhaler, a dry-powder inhaler and a soft-mist inhaler deliver the drug in fundamentally different ways, with different particle sizes and completely different techniques — one needs a slow steady breath, another a quick forceful one. Get the technique wrong and the drug coats your throat instead of reaching your lungs: all of the thrush, none of the benefit. If your inhaler doesn't seem to be working, the problem is often not the drug but the way it is being taken. Ask a pharmacist to watch you use it. It is the cheapest upgrade in asthma care.
Use the prescribed plan. GINA includes ICS-containing reliever regimens as well as daily maintenance. The choice depends on age, severity and the exact product. A spacer is for a compatible metered-dose aerosol, not a dry-powder inhaler. Ask a pharmacist to check the technique.